Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer

  • Byun, Sang Jun (Yongsan Health Subcenter) ;
  • Kim, Jin Hee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Oh, Young Kee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Byung Hoon (Department of Urology, Dongsan Medical Center, Keimyung University School of Medicine)
  • Received : 2015.08.26
  • Accepted : 2015.10.22
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate survival rates and prognostic factors related to treatment outcomes after bladder preserving therapy including transurethral resection of bladder tumor, radiotherapy (RT) with or without concurrent chemotherapy in bladder cancer with a curative intent. Materials and Methods: We retrospectively studied 50 bladder cancer patients treated with bladder-preserving therapy at Keimyung University Dongsan Medical Center from January 1999 to December 2010. Age ranged from 46 to 89 years (median, 71.5 years). Bladder cancer was the American Joint Committee on Cancer (AJCC) stage II, III, and IV in 9, 27, and 14 patients, respectively. Thirty patients were treated with concurrent chemoradiotherapy (CCRT) and 20 patients with RT alone. Nine patients received chemotherapy prior to CCRT or RT alone. Radiation was delivered with a four-field box technique (median, 63 Gy; range, 48.6 to 70.2 Gy). The follow-up periods ranged from 2 to 169 months (median, 34 months). Results: Thirty patients (60%) showed complete response and 13 (26%) a partial response. All patients could have their own bladder preserved. Five-year overall survival (OS) rate was 37.2%, and the 5-year disease-free survival (DFS) rate was 30.2%. In multivariate analysis, tumor grade and CCRT were statistically significant in OS. Conclusion: Tumor grade was a significant prognostic factor related to OS. CCRT is also considered to improve survival outcomes. Further multi-institutional studies are needed to elucidate the impact of RT in bladder cancer.

Keywords

References

  1. Petrovich Z, Jozsef G, Brady LW. Radiotherapy for carcinoma of the bladder: a review. Am J Clin Oncol 2001;24:1-9. https://doi.org/10.1097/00000421-200102000-00001
  2. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006;24: 5536-44. https://doi.org/10.1200/JCO.2006.07.6729
  3. Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, Harrison SC. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 2003;43:246-57. https://doi.org/10.1016/S0302-2838(02)00581-X
  4. Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995; 31:247-54. https://doi.org/10.1016/0360-3016(94)E0135-7
  5. Gospodarowicz MK, Hawkins NV, Rawlings GA, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142:1448-53. https://doi.org/10.1016/S0022-5347(17)39122-X
  6. Pollack A, Zagars GZ. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 1996;14:86-95.
  7. De Neve W, Lybeert ML, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995;36: 183-8. https://doi.org/10.1016/0167-8140(95)01586-6
  8. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986;7:299-310. https://doi.org/10.1016/S0167-8140(86)80059-7
  9. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014;32:3801-9. https://doi.org/10.1200/JCO.2014.57.5548
  10. Munro NP, Sundaram SK, Weston PM, et al. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys 2010;77:119-24. https://doi.org/10.1016/j.ijrobp.2009.04.050
  11. Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008;70:456-63. https://doi.org/10.1016/j.ijrobp.2007.06.030
  12. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today: a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690-6. https://doi.org/10.1200/JCO.2003.05.101
  13. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111-6. https://doi.org/10.1016/S0022-5347(05)66440-3
  14. Yu JI, Park W, Oh DR, et al. Bladder preserving treatment in patients with muscle invasive bladder cancer. J Korean Soc Ther Radiol Oncol 2007;25:70-8.
  15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. https://doi.org/10.1097/00000421-198212000-00014
  16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  17. Halperin EC, Wazer DE, Perez CA, Brady LW. Perez and Brady's principles and practice of radiation oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
  18. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation: the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14: 2901-7. https://doi.org/10.1200/JCO.1996.14.11.2901
  19. Wallace DM, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991;67:608-15. https://doi.org/10.1111/j.1464-410X.1991.tb15225.x
  20. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.
  21. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combinedmodality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-11. https://doi.org/10.1016/j.eururo.2011.11.010
  22. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-83. https://doi.org/10.1200/JCO.1998.16.11.3576
  23. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: longterm outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62-7.

Cited by

  1. Biodistribution of gold nanoparticles in BBN-induced muscle-invasive bladder cancer in mice vol.12, pp.None, 2015, https://doi.org/10.2147/ijn.s140977
  2. Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis vol.8, pp.40, 2015, https://doi.org/10.18632/oncotarget.16576
  3. Trimodal therapy for muscle-invasive bladder cancer vol.18, pp.12, 2015, https://doi.org/10.1080/14737140.2018.1535314
  4. Effect of body thickness on helical and direct treatment delivery modes: a phantom study vol.13, pp.2, 2018, https://doi.org/10.2185/jrm.2965
  5. A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16) vol.14, pp.1, 2015, https://doi.org/10.1371/journal.pone.0209998
  6. Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis vol.10, pp.None, 2015, https://doi.org/10.3389/fonc.2020.564779
  7. Survival Impact of Current-Smoking-Related COPD or COPD with Acute Exacerbation on Bladder Preservation through Concurrent Chemoradiotherapy for Muscle-Invasive Bladder Urothelial Carcinoma vol.11, pp.10, 2021, https://doi.org/10.3390/jpm11100958